Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

TimesSquare Capital Management U.S. Mid Cap Growth Strategy 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (TimesSquare Capital Management U.S. Mid Cap Growth Strategy)

Primary Source Intelligence • Q1 2024 Letter Analysis

TimesSquare Capital Management U.S. Mid Cap Growth Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, TimesSquare Capital Management U.S. Mid Cap Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+9.14%

Digest Analysis

Quick Take

"TimesSquare's mid-cap growth strategy outperformed in Q1 2024, capitalizing on AI infrastructure themes and cybersecurity demand."

Executive Summary

TimesSquare Capital Management's U.S. Mid Cap Growth strategy outperformed the Russell Midcap Growth Index in Q1 2024, returning 9.95% net versus the benchmark's 9.50%. The portfolio benefited from exposure to AI infrastructure themes, with GenAI capital expenditures driving technology sector performance led by NVIDIA's 82% gain. Key contributors included CrowdStrike Holdings, which expanded beyond endpoint security to comprehensive cloud workload protection, and EMCOR Group, which posted record backlogs in electrical and mechanical systems. The team positioned around several investment dynamics: GenAI's shift toward data preparation applications, data centers' growing power demands potentially reaching 20-25% of U.S. consumption, and regional energy self-sufficiency driving industrial activity. Healthcare utilization strengthened beyond GLP-1 themes, while consumer spending remained mixed with value-conscious behavior. Portfolio actions included trimming outperformers like O'Reilly Automotive and Interactive Brokers Group, adding to Legend Biotech and Verisk Analytics on weakness, and exiting Aptiv due to EV component headwinds. The strategy maintains focus on companies with quality management, competitive advantages, and sustainable growth positioned for structural trends.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

High-moderate conviction evidenced by 17 named positions with specific performance attribution, clear thesis explanations, and decisive portfolio actions including exits and additions. The 75-stock portfolio structure and detailed individual position commentary demonstrate meaningful conviction in holdings, though diversification caps the score below high conviction levels.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism noting strong Q1 performance and global economic expansion, but acknowledges mixed consumer spending trends and maintains focus on bottom-up fundamentals rather than broad market enthusiasm.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

Portfolio positioning shows selective risk-taking with active trimming of outperformers and adding to positions on weakness. The approach demonstrates measured risk appetite rather than aggressive deployment or defensive positioning.

Capital Deployment

48%

De-riskingDeploying

Net Neutral (48%)

Net neutral to slight de-risking activity with multiple position trims following strong performance (O'Reilly, Interactive Brokers, Encompass Health, Waste Connections, Hexcel) partially offset by additions to Legend Biotech and Verisk Analytics. The trimming of winners suggests modest profit-taking rather than aggressive deployment.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

Forward guidance is cautious and monitoring-focused, emphasizing watching central banks and elections while seeking fundamental underpinnings to valuations. No clear bias toward aggressive deployment or defensive positioning.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with opportunity-focused discussion of AI infrastructure and cybersecurity themes offset by cautious consumer spending commentary and mixed outlook references. Slightly more constructive than bearish overall.

Perceived Risk

25%

Low RiskElevated

Low Risk (25%)

Low-moderate risk perception with brief mentions of consumer value consciousness, mixed spending trends, and regulatory concerns for Encompass Health. No systemic risk warnings or detailed downside scenarios discussed. Risk acknowledgment is present but not central to the letter.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Moderate-high opportunity density with manager identifying multiple structural themes including AI infrastructure evolution, data center power demands, cybersecurity growth, and energy self-sufficiency. Active position management and new theme identification suggest a reasonably rich opportunity set.

Time Horizon

60%

Short-TermLong-Term

Multi-Year (60%)

Medium-term horizon with focus on structural themes like GenAI evolution and data center power demands expected to play out over multiple years. Some catalyst dependency mentioned but emphasis on sustainable competitive advantages and business fundamentals suggests 2-3 year investment timeframes.